Semaglutide vs Tirzepatide vs Retatrutide: Mechanism and Trial Data Compared
How semaglutide's single-receptor mechanism compares to tirzepatide's dual and retatrutide's triple agonism — and what the STEP, SURMOUNT and TRIUMPH trial data actually shows head-to-head.
Three compounds, one receptor family
Semaglutide, tirzepatide and retatrutide are often discussed together because they are structurally and mechanistically related, not because they are interchangeable. All three are synthetic peptides built around a fatty-diacid modification that binds serum albumin, giving each a multi-day half-life and a once-weekly research dosing schedule. Where they diverge is receptor count: semaglutide activates one receptor, tirzepatide two, retatrutide three. That single variable — how many of the GIP, GLP-1 and glucagon receptors a molecule engages — is the entire basis for comparing them, and it is what the Phase 3 data below is actually testing.
The mechanism, side by side
| Compound | Receptor target(s) | Approx. half-life | Key Phase 3 program |
|---|---|---|---|
| Semaglutide | GLP-1 (single) | ~1 week | STEP (Novo Nordisk) |
| Tirzepatide | GIP + GLP-1 (dual) | ~5 days | SURPASS / SURMOUNT (Eli Lilly) |
| Retatrutide | GIP + GLP-1 + glucagon (triple) | ~6 days | TRIUMPH (Eli Lilly) |
Each additional receptor is a deliberate engineering choice, not an accident of synthesis. Semaglutide's single GLP-1 target established the fatty-diacid, albumin-binding design that both later compounds reuse (Lau J et al., 2015, J Med Chem; PMID 26308095). Tirzepatide keeps that backbone and adds GIP-receptor activity through an imbalanced potency profile. Retatrutide keeps tirzepatide's GIP/GLP-1 pairing and adds glucagon-receptor agonism through a shorter C18 fatty-diacid chain at a different lysine position — the structural change covered in full on our Retatrutide research profile and Tirzepatide research profile.
Semaglutide: the single-receptor original
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk, marketed as Ozempic (FDA-approved December 2017, for type 2 diabetes) and Wegovy (FDA-approved June 2021, for chronic weight management). It is the longest-approved of the three compounds discussed here, and the only one with published long-term cardiovascular outcomes data: the SUSTAIN-6 trial (Marso SP et al., 2016, N Engl J Med; PMID 27633186) reported major adverse cardiovascular events in 6.6% of the semaglutide group against 8.9% on placebo, a hazard ratio of 0.74.
On weight, the STEP 1 trial (Wilding JPH et al., 2021, N Engl J Med; PMID 33567185) reported 14.9% mean body-weight loss at 68 weeks on the 2.4 mg dose, against 2.4% on placebo — the result that established GLP-1 monotherapy's ceiling and the benchmark every dual- and triple-agonist compound since has been measured against.
Tirzepatide: adding the GIP receptor
Tirzepatide pairs GLP-1 agonism with GIP-receptor activity, reported at roughly 5-fold greater potency at the GIP receptor than native GIP itself. The SURMOUNT-1 trial reported 20.9% mean weight loss at 72 weeks on the 15 mg dose against 3.1% on placebo, and the SURPASS program reported HbA1c reductions of up to 2.07% in type 2 diabetes — both ahead of semaglutide's single-receptor results in their respective trials. The full mechanism, structural detail and trial breakdown is on our Tirzepatide research profile; doses are on the product page.
Retatrutide: adding a third, glucagon
Retatrutide keeps tirzepatide's two receptors and adds glucagon-receptor agonism, which is reported to increase hepatic lipid oxidation and energy expenditure alongside the appetite and glycaemic effects the other two receptors provide. It is the newest and least mature of the three programs: TRIUMPH-4, the first Phase 3 readout, reported 28.7% mean body-weight loss at 68 weeks on the 12 mg dose against 2.1% on placebo — the highest figure yet recorded in a Phase 3 obesity trial for any compound in this class. Three further TRIUMPH readouts are expected through 2026. The full breakdown is on our Retatrutide research profile; doses are on the product page.
What the trials actually show head-to-head
Only one of the three possible pairings has been tested in a genuine randomised head-to-head trial. SURMOUNT-5 (Aronne LJ et al., 2025, N Engl J Med; PMID 40353578) enrolled 751 adults without type 2 diabetes and randomised them directly to tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg). At 72 weeks, tirzepatide produced 20.2% mean weight loss against semaglutide's 13.7% — a statistically significant difference (p<0.001) inside a single trial, which is the only comparison here that supports a direct "more effective than" claim.
Retatrutide has not been tested against either compound in a head-to-head trial. TRIUMPH-4's 28.7% figure and SURMOUNT-1's 20.9% figure come from separate trials, run in different populations (TRIUMPH-4 specifically enrolled participants with knee osteoarthritis alongside obesity), over different exact durations and dose-escalation schedules. Comparing the two headline numbers directly is a common shorthand, including in research commentary, but it is not the same evidence as SURMOUNT-5's direct randomisation, and retatrutide's own Phase 3 program — designed to confirm its Phase 2 results at scale — is not yet complete.
Reported results, side by side
| Compound | Headline trial result | Regulatory status (branded form) |
|---|---|---|
| Semaglutide | 14.9% weight loss at 68 weeks (STEP 1, 2.4 mg) vs 2.4% placebo | FDA-approved: Ozempic (T2D, 2017), Wegovy (weight, 2021) |
| Tirzepatide | 20.9% weight loss at 72 weeks (SURMOUNT-1, 15 mg) vs 3.1% placebo | FDA-approved: Mounjaro (T2D, 2022), Zepbound (weight, 2023) |
| Retatrutide | 28.7% weight loss at 68 weeks (TRIUMPH-4, 12 mg) vs 2.1% placebo | Investigational — not approved by the FDA, the NPRA, or any regulator |
None of the compounds discussed here are registered with Malaysia's National Pharmaceutical Regulatory Agency or approved for human use in Malaysia. Semaglutide's and tirzepatide's branded, prescription-only forms are approved abroad for the indications above, used under medical supervision; retatrutide remains investigational everywhere, with no approval in any jurisdiction. Tirzepatide and retatrutide, as sold on this site, are unbranded compounds supplied strictly for laboratory research use — not the approved medication, and not for human use.
Choosing between them for research
The receptor count is the practical starting point for deciding which compound a given research question calls for. Work isolating GLP-1 pathway effects on its own has semaglutide's single-receptor profile and the deepest evidence base, including the only long-term cardiovascular outcomes data of the three. Work examining GIP/GLP-1 synergy has tirzepatide's SURPASS and SURMOUNT programs, the largest Phase 3 dataset in the class and the only direct head-to-head comparison available. Work on glucagon-receptor contribution to energy expenditure and hepatic fat has retatrutide, at the earliest and least-confirmed stage of the three. See the Tirzepatide and Retatrutide research profiles for the full structural and trial detail behind each.
This article summarises published Phase 2 and Phase 3 trial data for research orientation. It is not medical advice, and none of the compounds discussed are indications for self-treatment. Cited figures are drawn from the primary trial publications linked above.